Loading…
Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
Remdesivir, a monophosphate prodrug of nucleoside analog GS-441524, is widely used for the treatment of moderate to severe COVID-19. It has been suggested to use GS-441524 instead of remdesivir in the clinic and in new inhalation formulations. Thus, we compared the anti-SARS-CoV-2 activity of remdes...
Saved in:
Published in: | Current research in pharmacology and drug discovery 2021-01, Vol.2, p.100045-100045, Article 100045 |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Remdesivir, a monophosphate prodrug of nucleoside analog GS-441524, is widely used for the treatment of moderate to severe COVID-19. It has been suggested to use GS-441524 instead of remdesivir in the clinic and in new inhalation formulations. Thus, we compared the anti-SARS-CoV-2 activity of remdesivir and GS-441524 in Vero E6, Vero CCL-81, Calu-3, Caco-2 cells, and anti-HCoV-OC43 activity in Huh-7 cells. We also compared the cellular pharmacology of these two compounds in Vero E6, Vero CCL-81, Calu-3, Caco-2, Huh-7, 293T, BHK-21, 3T3 and human airway epithelial (HAE) cells. Overall, remdesivir exhibited greater potency and superior intracellular metabolism than GS-441524 except in Vero E6 and Vero CCL-81 cells.
[Display omitted]
•Anti-SARS-CoV-2 potency of remdesivir is similar to GS-441524 in Vero cells, but higher in Calu-3 and Caco-2 cells.•Anti-HCoV-OC43 activity of remdesivir is higher than GS-441524 in Huh-7 cells.•Cellular level of GS-443902 positively correlates with the anti-coronavirus activity in Calu-3, Caco-2 and Huh-7 cells.•Remdesivir exhibits superior cellular metabolism than GS-441524 in 293T, BHK-21, 3T3 and human airway epithelial cells. |
---|---|
ISSN: | 2590-2571 2590-2571 |
DOI: | 10.1016/j.crphar.2021.100045 |